Abstract
Background: Although mainstream guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in patients following transcatheter aortic valve replacement (TAVR), it is not evidence-based. We aim to investigate the safety and efficacy of DAPT vs. single antiplatelet therapy (SAPT) after TAVR, and review updated evidence. Methods: We systematically searched PubMed, Embase, and Cochrane for studies comparing DAPT to SAPT after TAVR from inception to November 30, 2020. Results: Twelve studies of 20,766 patients were included. Compared with SAPT, DAPT was associated with an increased risk for combined life-threatening and major bleeding [OR 1.73 (1.19-2.51), p = 0.004]. There were no significant differences in major adverse cardiovascular events (MACE), cardiovascular mortality, or stroke. Conclusions: Post-TAVR DAPT increases bleeding risk without additional thrombotic protection.
Introduction
Transcatheter Aortic Valve Replacement (TAVR) has revolutionized the treatment of severe aortic stenosis, providing a minimally invasive alternative to open-heart surgery. However, a significant post-operative concern is the formation of blood clots on the new prosthetic valve, which can lead to strokes or myocardial infarctions (MI). To mitigate this risk, clinical guidelines have traditionally recommended Dual Antiplatelet Therapy (DAPT)—typically a combination of aspirin and clopidogrel—for the first 3–6 months.
This recommendation was largely based on expert consensus rather than robust clinical trial data. Antiplatelet drugs are a double-edged sword: while they prevent thrombosis, they also increase the risk of dangerous bleeding. This paper investigates whether the standard DAPT approach is truly beneficial or if Single Antiplatelet Therapy (SAPT)—usually aspirin alone—is sufficient and safer for patients.
Methods
The authors conducted a systematic review and meta-analysis following PRISMA guidelines. They searched major medical databases (PubMed, Embase, Cochrane) for studies comparing DAPT to SAPT after TAVR through November 2020.
The analysis synthesized data from 12 studies involving a total of 20,766 patients. This included four Randomized Controlled Trials (RCTs) and eight high-quality observational studies. The primary focus was Major Adverse Cardiac and Cerebrovascular Events (MACE), which includes mortality, MI, stroke, and major or life-threatening bleeding (LTB). The quality of evidence was assessed using the GRADE system and Cochrane Risk of Bias tools.
Results
The meta-analysis revealed that DAPT significantly increases the risk of bleeding without providing extra protection against thrombotic events. Key findings include:
- Increased Bleeding Risk: DAPT was associated with a significantly higher risk of combined life-threatening and major bleeding (OR 1.73, p = 0.004). When isolated, major bleeding was even more prevalent in the DAPT group (OR 2.29, p < 0.001).
- Thrombotic Neutrality: There were no statistically significant differences between DAPT and SAPT in terms of MACE (OR 1.19, p = 0.07), cardiovascular mortality (OR 1.46, p = 0.10), or stroke (OR 0.97, p = 0.71).
The increased bleeding risk with DAPT was consistent across both randomized trials and observational data. While some observational studies suggested a mortality benefit for DAPT, this was likely due to selection bias, as this benefit disappeared when looking strictly at randomized trials.
Discussion
The findings suggest that the "more is better" philosophy in antiplatelet therapy is flawed in the context of TAVR. The lack of additional benefit from clopidogrel suggests that aspirin alone provides sufficient protection during the valve's endothelialization phase. The significant bleeding penalty associated with DAPT can negate the clinical benefits of the TAVR procedure itself.
This study provides a strong evidence base for updating international clinical guidelines to favor SAPT. However, the authors acknowledge limitations, such as the heavy weighting of one large registry study and variations in follow-up duration across the included trials. Future work should focus on large-scale RCTs to refine the optimal duration of therapy and identify specific patient subgroups that might still require more intensive regimens.
Conclusion
Compared with SAPT, post-TAVR DAPT is associated with increased risks of major or life-threatening bleeding without additional benefits in reducing thrombotic events. These findings support a shift toward Single Antiplatelet Therapy as the safer clinical standard for patients following TAVR.
Summary updated